Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. M. Sand, F. Genovese, F. Martinez, M. Han, C. Hogaboam, M. A. Karsdal, D. J. Leeming (Herlev, Denmark; Ann Arbor, United States Of America). Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients. Eur Respir J 2013; 42: Suppl. 57, 838

Member's Comments

No comment yet.

Related content which might interest you: Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 A neo-epitope of collagen type VII (C7) is elevated in serum of patients with COPD and SSC Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Collagen degradation profile in serum of patients with COPD or IPF Source: Annual Congress 2012 - Monitoring of airway diseases: far from the airways Year: 2012 Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Serologically assessed elastin degradation is related to force vital capacity in patients with IPF Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench Year: 2013 Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulmonary gene expression of tenascin-C and fibronectin in chronic obtructive pulmonary disease (COPD) Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Serum levels of leptin and visfatin in chronic obstructive pulmonary disease Source: International Congress 2015 – Different data in COPD Year: 2015 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Serum angiopoietin-2 levels in stable and exacerbated chronic obstructive pulmonary disease Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema Year: 2015 MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016